Note: Descriptions are shown in the official language in which they were submitted.
WO 2021/081292
PCT/US2020/057001
METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR
PARTIAL AGONISTS
CROSS-REFERENCE TO RELATED APPLICATIONS
100011 This application claims benefit of priority under 35 U.S.C. 119(e) of
U.S. Serial No.
62/926,392, filed October 25, 2019, the entire contents of which is
incorporated herein by
reference in its entirety.
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
100021 The present disclosure in various aspects and embodiments relates to
compositions
and methods for treating a brain-related disease or disorder in a patient.
BACKGROUND INFORMATION
100031 PCT Patent Application Publication No.
W02008112773 states "the application is
directed to the use of droxidopa, alone or in combination with one or more
additional
components, for the treatment of conditions, such as neuronally mediated
postural
hypotension."
100041 US Patent No. 5,952,362 discloses "various 2-
imidazoline, 2-oxazoline, 2-
thiazoline, and 4-imidazole derivatives of methylphenyl, methoxyphenyl, and
aminophenyl
alkyl sulfonamides and ureas" and "includes the use of the above compounds,
and compositions
containing them, as alphaiAin, agonists in the treatment of various disease
states such as urinary
incontinence, nasal congestion, priapism, depression, anxiety, dementia,
senility, Alzheimer's,
deficiencies in attentiveness and cognition, and eating disorders such as
obesity, bulimia, and
anorexia." The '362 patent discloses the compound N46-chloro-3-(4,5-dihydro-1H-
imidazol-
2-ylmethoxy)-2-methylphenyl] methanesulfonamide hydrochloride.
SUMMARY OF THE INVENTION
100051 Current treatments for nOH (e.g., indirect
sympathomimetic droxidopa / Northera
or the non-selective al-AR agonist midodrine) often result in a risk of supine
hypertension.
Accordingly, as discussed in more detail elsewhere herein it is one goal of at
least some of the
methods and disclosed herein to use a selective aiA-AR partial agonist to
alleviate symptoms
of nOH by moderately activating smooth muscles in the venous vascular branches
through aiA-
AR receptors, while sparing the arteriolar smooth muscles (largely am-AR and
alp-AR
function), thus mitigating an increase peripheral vascular resistance (no
'afterload' elevation)
that results in the supine hypertension caused by other nOH treatments.
1
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
100061 As such, in a first aspect, a method is provided
that includes identifying a patient
diagnosed with nOH or in need of treatment for nOH and administering to said
patient an aiA-
AR partial agonist. In some embodiments, a patient diagnosed with nOH meet at
least one or
more of the following diagnostic criteria: (1) demonstrate a a-30 mm Hg (or 20
mm Hg; or
a'25 mm Hg; or 35 mm Hg) drop in SBP within 5 minutes of standing; (2)
demonstrate
impaired autonomic reflexes as determined by absence of BP overshoot during
phase IV of the
Valsalva maneuver; (3) experience dizziness, light-headedness, or fainting
when standing; and
(4) have an absence of other identifiable causes of autonomic neuropathy. In
some
embodiments a patient diagnosed with nOH meet at least two; or at least three;
or all four of
the diagnostic criteria.
100071 In another aspect, a method is provided that
includes identifying a patient diagnosed
with nOH or in need of treatment for nOH and administering to said patient an
atA-AR partial
agonist; wherein peripheral vascular resistance in said patient is not
markedly raised (no
`afterload' elevation). In a related aspect, a method is provided that
includes identifying a
patient diagnosed with nOH or in need of treatment for nOH and administering
to said patient
an aiA-AR partial agonist; wherein the supine systolic blood pressure in said
patient does not
rise more than 5%; or more than 10%; or more than 15%; or more than 20%; or
more than
25%; or more than 30%; or more than 35%; or more than 40%; or more than 45%;
or more
than 50%, or more than 60%; or more than 70%; or more than 75%, or more than
80%, or more
than 90%; or more than 100% as compared to the patient's blood pressure prior
to
administration of the aiA-AR partial agonist.
100081 The term "partial agonist" as used herein means a
ligand that acts as an agonist to a
receptor but does not reach the maximal response capability of the system even
at full receptor
occupancy; Le., a partial agonist produces sub-maximal activation even when
occupying the
total receptor population, therefore cannot produce the maximal response,
irrespective of the
concentration applied. In some embodiments, a partial agonist exhibits a
maximum efficacy
that is less than 1% or; 5%; or 10%; or 15%; or 20%; or 25%; or 30 ,6; or 35%;
or 40%; or
45%; or 50%; or 55%; or 60%; or 65%; or 70%; or 75%; or 80%; or 85% of the
efficacy of a
corresponding full agonist of the same receptor.
100091 The term "aiA-AR partial agonist" as used herein
means a ligand that is a partial
agonist of the aiA-AR receptor. Specific examples of an aiA-AR partial agonist
include
R01151240 (dabuzalgron) and Compound-B. In some embodiments an alA-AR partial
agonist
2
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
exhibits a maximum efficacy (or intrinsic activity, "IA") that is less than
10%; or less than
15%; or less than 20%; or less than 25%; or less than 30%; or less than 35%;
or less than 40%;
or less than 45%; or less than 50%; or less than 55%; or less than 60%; or
less than 65%; or
less than 70%; or less than 75%; or less than 80%; or less than 85% or between
15 and 75%;
or between 20 and 65%; or between 20 and 60%; or between 20 and 55%; or
between 20 and
50%; or between 20 and 45%; or between 25 and 60%; or between 25 and 55%; or
between 25
and 35%; or between 30 and 40%; or between 40 and 50%; or between 45 and 55%;
of the
intrinsic activity of a corresponding full agonist of the aiA-AR receptor
(examples of a full
agonist of the aiA-AR receptor include noradrenaline and amidephrine). In
certain related
embodiments, In some embodiments an aiA-AR partial agonist exhibits a maximum
efficacy
(or intrinsic activity, "IA") that is less than 30%; or less than 35%; or less
than 40%; or less
than 45%, or less than 50%; or less than 55%; or less than 60%; or less than
65%; or less than
70%; or less than 75%; or less than 80%; or less than 85% --but that is
greater than 5%; or
10%; or 15% or 20%. Blue et at, BJU International, (2004) 93:162-170 (hereby
incorporated
by reference in its entirety) provides compositions and methods that can be
used to determine
partial agonism, and partial agonism of the aiA-AR receptor in particular, and
demonstrates
exemplary aiA-AR partial agonists. In certain embodiments, an aiA-AR partial
agonist has less
than 35%; or less than 40%; or less than 45%; or less than 50%; or less than
55%; or less than
60%; or less than 65%; or less than 70%; or less than 75%; or less than 80%;
or less than 85%;
or between 15 and 75%; or between 20 and 65%; or between 25 and 60%; or
between 25 and
55%; or between 25 and 35%; or between 30 and 40%; or between 40 and 50%; or
between 45
and 55% of the activity of a full agonist using the InsPs accumulation assay
described in Blue
et al. (see, for example, Blue et. at, Table 1 showing an intrinsic activity
of 0.31 for RO 115-
1240 (dabuzalgron) free base and 0.27 for RO 115-1240 (dabuzalgron) HCI salt
as compared
to noradrenaline in the InsPs accumulation assay). In some embodiments, an aiA-
AR partial
agonist has less than 35%; or less than 40%; or less than 45%; or less than
50%; or less than
55%; or less than 60%; or less than 65%; or less than 70%; or less than 75%;
or less than 80%;
or less than 85% or between 15 and 75%; or between 20 and 65%; or between 25
and 60%; or
between 25 and 55%; or between 25 and 35%; or between 30 and 40%; or between
40 and
50%; or between 45 and 55% of the activity of a full agonist using the FLIPR
assay described
in Blue et at (see, for example, Blue et at, Table 1 showing an intrinsic
activity of 0.51 for
RO 115-1240 (dabuzalgron) HO salt as compared to noradrenaline in the FLIPR
assay). In
3
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
many embodiments, an (HA-AR partial agonist may have a similar affinity for
the atA-AR as
compared to a full agonist. The term aiA-AR partial agonist as used herein
contemplates in
some embodiments any pharmaceutically acceptable salt, or prodrug thereof
100101 In some embodiments, an atA-AR partial agonist is
a selective ctiA-AR partial
agonist. As used herein a "selective atA-AR partial agonist" exhibits partial
agonism for atA-
AR receptors but does not exhibit appreciable agonism for other receptors such
as other at-AR
subtypes (e.g., am-AR or atp-AR). Blue et at, BJU International, (2004) 93:162-
170 (hereby
incorporated by reference in its entirety) provides compositions and methods
that can be used
to determine selective agonism (and selective partial agonism), and selective
agonism (and
selective partial agonism) of the aiA-AR receptor in particular, and
demonstrates exemplary
selectivities as WA-AR partial agonists. In some embodiments, a selective atA-
AR agonist or
a selective atA-AR partial agonist as used herein does not exhibit agonist
activity for other
receptors including am-AR or am-AR receptors (for example in CHO cells
expressing am-AR
or am-AR using the methods described in Blue et al). In some embodiments a
selective atA-
AR agonist or a selective atA-AR partial agonist as used herein has a pECso
for am-AR and
CUD-AR receptors that is less than 8.0; or less than 7.5; or less than 7.0; or
less than 6.5; or less
than 6.0; or less than 5.5; or less than 5; or less than 4.5; or less than 4;
or less than 3.5; or
between 2.5 and 6; or between 3 and 5.5; or between 3 and 5.0; or between 3
and 5. In some
embodiments a selective aa-AR agonist or a selective WA-AR partial agonist as
used herein
has a pEC50 for ats-AR and am-AR receptors that is less than 7.0; or less than
6.5; or less than
6.0; or less than 5.5; or less than 5; or less than 4.5; or less than 4; or
less than 3.5; or between
2.5 and 6; or between 3 and 5.5; or between 3 and 5.0; or between 3 and 5
using the InsPs
accumulation assay described in Blue et at (see, for example, Blue et at,
Table 1 showing
pEC.50 of >4.0 for RO 115-1240 (dabuzalgron) free base and HCI salt for am-AR
and atp-AR
receptors in the InsPs accumulation assay). In some embodiments a selective
atA-AR agonist
or a selective alik-AR partial agonist as used herein has a pECso for am-AR
and am-AR
receptors that is less than 7.0; or less than 6.5; or less than 6.0; or less
than 5.5; or less than 5;
or less than 4.5; or less than 4; or less than 3.5; or between 2.5 and 6; or
between 3 and 5.5; or
between 3 and 5.0; or between 3 and 5 using the FL1PR assay described in Blue
et al (see, for
example, Blue et at, Table 1 showing pEC50 of >5.0 for RO 115-1240
(dabuzalgron) free base
and HCI salt for am-AR and am-AR receptors in the FLIPR accumulation assay).
In some
embodiments a selective auk-AR agonist or a selective auk-AR partial agonist
as used herein
4
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
has a pECsa for am-AR and aiD-AR receptors that is less than 85%; or less than
80%; or less
than 75%; or less than 65%; or less than 60%; or less than 55%; or less than
50% of that of a
non-selective agonist such as noradrenaline. In some embodiments a selective
aiA-AR agonist
or a selective aiA-AR partial agonist as used herein has a pEC50 for CUB-AR
and am-AR
receptors that is less than 85%; or less than 80%; or less than 75%; or less
than 65%; or less
than 60%; or less than 55%; or less than 50% of that of a non-selective
agonist such as
noradrenaline using the InsPs accumulation assay described in Blue et al. In
some
embodiments a selective aiA-AR agonist or a selective cuA-AR partial agonist
as used herein
has a pECso for am-AR and aiD-AR receptors that is less than 85%; or less than
80%; or less
than 75%; or less than 65%; or less than 60%; or less than 55%; or less than
50% of that of a
non-selective agonist such as noradrenaline using the FLIPR assay described in
Blue et al. In
some embodiments, a selective ctiA-AR agonist or a selective aiA-AR partial
agonist as used
herein does not exhibit agonist activity for other receptors including am-AR
or atD-AR
receptors (for example in CHO cells expressing am-AR or am-AR using the
methods described
in Blue et al.) at a concentration of 30 piMol/L or less; 50 pMol/L or less;
75 pMol/L or less;
or 100 itMol/L or less. In some embodiments a selective aiA-AR agonist or a
selective MA-
AR partial agonist does not bind to other receptors with a pKi higher than
5.5; or higher than
6.0; or higher than 6.5; or higher than 7.0; or higher than 7.2; or higher
than 7.5; or higher than
7.8; or higher than 8.0; or higher than 9.0 (for example using methodologies
described in Blue
et al). In some embodiments a selective aiA-AR agonist or a selective WA-AR
partial agonist
does not bind to am-AR or am-AR receptors with a IAA higher than 5.0; or
higher than 5.5; or
higher than 6.0; or higher than 7.0; or higher than 8.0; or higher than 9.0
(for example using
methodologies described in Blue et al).
[0011] The term "dabuzalgron," or "R01151240," or "Ro 115-
1240," as used herein
means the compound N46-chloro-3-(4,5-
dihydro-1H-imidazol-2-ylmethoxy)-2-
methylphenyl] methanesulfonamide, having the chemical structure as follows
(see
WO/2017/147532):
H3
Nee)
CH3S02NH
0.,,.....,,AN
is
CI
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
[0012] In some embodiments, term "dabuzalgron," or
"R01151240," or "Ro 115-1240,"
as used herein is a pharmaceutically acceptable salt (such as hydrochloride)
or prodrug thereof;
in other embodiments it is the free base thereof Blue et al., RAI
International, (2004) 93:162-
170 (hereby incorporated by reference in its entirety) provides
characteristics of dabuzalgron,
including its partial agonistic activities on the aiA-AR and its specificity
for the am-AR.
[0013] The term "Compound-B" as used herein means the
compound N-[2-chloro-4-(4,5-
dihydro-1H-imidazol-2-ylmethyl)-phenyl]-methanesulfonamide having the chemical
structure
as follows:
CI,
s,
H
100141 In some embodiments, term "Compound-B" as used
herein is a pharmaceutically
acceptable salt (such as hydrochloride) or prodrug thereof; in other
embodiments it is the free
base thereof
[0015] The term neurogenic orthostatic hypotension (nOH)
as used herein means a
condition in which a subject experiences a sustained drop in blood pressure
when changing
positions or standing from supine or sitting postures. Symptoms of nOH can
include dizziness,
lightheadedness and/or a feeling that one may blackout, especially upon
suddenly standing or
changing position. nOH can be associated with various neurologic disorders,
such
as Parkinson's disease, multiple system atrophy (MSA), and pure autonomic
failure (PAH).
More detail on the definition, diagnosis, and characterization of nOH and its
etiology is
provided elsewhere herein
[0016] In a further aspect, a method is provided that
includes identifying a patient
diagnosed with, or in need of treatment for, a disease or condition associated
with low cerebral
blood flow (CBF) and/or fluctuations in CBE and administering to the patient
an auk-AR partial
agonist. In a further aspect, a method is provided that includes identifying a
patient diagnosed
with, or in need of treatment for, symptoms caused by low cerebral blood flow
(CBF) and/or
fluctuations in CBF and administering to the patient an atA-AR partial
agonist. In some
6
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
embodiments, the disease or condition associated with low cerebral blood flow
(CBF) and/or
fluctuations in CBF is one or more selected from the group consisting of n0H,
cognitive
disorders, dementia with Levvy bodies, Parkinson's disease dementia,
Alzheimer's disease,
MSA, PAH. In some embodiments, the patient to be treated by the methods
disclosed herein
has experienced cognitive fluctuations; for example cognitive fluctuations
associated with
dementia with Lewy bodies (DLB) or with Parkinson's disease dementia (PDD)
(see Riley and
Espay, Journal of Clinical Movement Disorders, (2018) 5:1).
[0017] In yet another aspect, a method is provided that
includes identifying a patient in
need of a treatment to increase cardiac output and/or to increase venous
return and
administering to the patient an am-AR partial agonist
[0018] In yet another aspect, a method is provided that
includes (1) administering to a
patient an aiA-AR partial agonist, (2) monitoring blood pressure, cardiac
contractility and
output, ejection fraction, and/or venous return in said patient and (3)
decreasing the dose of
said am-AR partial agonist if the supine systolic blood pressure in the
patient rises above 150;
or 155; or 175; or 180; or 185; or 190; or 195; or 200; or 210; or 215; or
220; or 225.
[0019] In some embodiments provided is a method of
treating a patient such as
contemplated herein wherein, the method includes administering to a patient an
am-AR partial
agonist at a daily dose of about 0.5mg; or about 1 mg; or about 5 mg; or about
10 mg; or about
20 mg; or about 25 mg. In some embodiments provided is a method of treating a
patient such
as contemplated herein wherein, the method includes administering to a patient
an am-AR
partial agonist at a daily dose of about 0.5mg; or about 1 mg; or about 3 mg;
or about 5 mg; or
about 7mg; or about 10 mg; or about 15 mg; or about 20 mg; or about 25 mg. In
some
embodiments provided is a method of treating a patient such as contemplated
herein wherein,
the method includes administering to a patient an am-AR partial agonist at a
dose of about
0.5mg; or about 1 mg; or about 5 mg; or about 10 mg; or about 20 mg; or about
25 mg. In
some embodiments provided is a method of treating a patient such as
contemplated herein
wherein, the method includes administering to a patient an am-AR partial
agonist at a daily
dose of about 0.1 jig/kg; 0.5 jig/kg; 1 pg/kg; or 5 pg/kg; or 10 jig/kg; or 15
pg/kg; or 20 pg/kg;
or 25 pg/kg; or 30 pg/kg; or 35 jig/kg; or 40 pg/kg; or 45 pig/kg; or 50
pg/kg; or 60 pg./kg; or
75 pg/kg; or 100 pg/kg; or 200 jig/kg; or 250 pg/kg; or 500 pg/kg; or 750
jig/kg; or 1 mg/kg.
[0020] In some embodiments provided is a method of
treating a patient such as
contemplated herein wherein, the method includes administering to a patient an
am-AR partial
7
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
agonist wherein the patient takes a dose of the atA-AR partial agonist once
daily; or twice daily;
or three times daily; or four times daily. In some embodiments the first dose
of the WA-AR
partial agonist is taken immediately after the patient wakes in the morning.
In some
embodiments the first dose of the atA-AR partial agonist is taken before noon.
In some
embodiments all doses of the atA-AR partial agonist are taken before sunset.
In some
embodiments the last dose of the atA-AR partial agonist for any particular day
is taken at least
about 1 hour; or at least about 2 hours; or at least about 3 hours; or at
least about 4 hours; or at
least about 5 hours; or at least about 6 hours before the patient goes to
sleep at night. In some
embodiments, the patient takes doses of the atA-AR partial agonist at an
interval of about 4
hours, about 5 hours; or about 6 hours. In some embodiments the patient takes
a single daily
dose of the WA-AR partial agonist shortly after waking. In some embodiments
the patient
takes a first dose of the atA-AR partial agonist shortly after waking and a
second dose 4-6 hours
later. In some embodiments the patient takes a first dose of the ctiA-AR
partial agonist shortly
after waking and a second dose about 4 hours later and a third dose about 4
hours after the
second dose. In certain embodiments, dosing earlier in the day lessens any
possible negative
impact of the atA-AR partial agonist on supine systolic blood pressure.
[0021] In certain embodiments of the methods described
herein, an atA-AR partial agonist
is used to treat symptomatic nOH caused by primary autonomic failure
(including pure
autonomic failure, multiple system atrophy and Parkinson's disease), or
autonomic neuropathy
(including diabetic and nondiabetic autonomic neuropathy). In another
embodiment, the patient
of a method as described herein has multiple system atrophy; and or the
patient has Parkinson's
disease.
[0022] In some embodiments of the methods as described
herein, the patient has pure
autonomic failure (PAF). In some embodiments of the methods as described
herein the patient
has multiple system atrophy (MSA). In some embodiments of the methods as
described herein,
the patient has symptomatic nOH caused by autonomic neuropathy.
[0023] In some embodiments of the methods as described
herein, the patient exhibits one
or more symptoms selected from the group consisting of slowness of movement,
tremor, or
rigidity (stiffness); clumsiness or incoordination; impaired speech, a croaky,
quivering voice;
fainting or lightheadedness due to orthostatic hypotension; bladder control
problems, such as a
sudden urge to urinate or difficulty emptying the bladder, stiffness, tremor,
problems of
balance, coordination, and autonomic nervous system dysfunction; ataxia
(problems with
8
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
balance and coordination), difficulty swallowing, speech abnormalities or a
quavering voice,
abnormal eye movements, orthostatic hypotension; dry mouth; rapid heart rate;
tunnel vision;
difficulty swallowing; bowel incontinence; blurry vision; urinary
incontinence; constipation;
anhydrosis; and sexual di sfunction.
[0024] In some embodiments of the methods of the aspects
and embodiments provided
herein, the patient is identified as having a one or more diseases or
disorders selected from the
group consisting of MCI (mild cognitive impairment), aMCI (amnestic MCI),
Vascular
Dementia, Mixed Dementia, FTD (fronto-temporal dementia; Pick's disease), HD
(Huntington
disease), Rett Syndrome, PSP (progressive supranuclear palsy), CBD
(corticobasal
degeneration), SCA (spinocerebellar ataxia), MSA (Multiple system atrophy),
SDS (Shy¨
Drager syndrome), olivopontocerebellar atrophy, TBI (traumatic brain injury),
CTE (chronic
traumatic encephalopathy), stroke, WKS (Wemicke-Korsakoff syndrome; alcoholic
dementia
& thiamine deficiency), normal pressure hydrocephalus, hypersomnia/narcolepsy,
ASD
(autistic spectrum disorders), FXS (fragile X syndrome), TSC (tuberous
sclerosis complex),
prion-related diseases (CJD etc.), depressive disorders, DLB (dementia with
Lewy bodies), PD
(Parkinson's disease), PDD (PD dementia), ADHD (attention deficit
hyperactivity disorder),
Alzheimer's disease (AD), early AD, and Down Syndrome (DS). In some
embodiments the of
the patient is identified as having a neurodegenerative disease that is one or
more selected from
the group consisting of MCI, aMCI, Vascular Dementia, Mixed Dementia, FTD
(fronto-
temporal dementia; Pick's disease), HID (Huntington disease), Rett Syndrome,
PSP
(progressive supranuclear palsy), CBD (corticobasal degeneration), SCA
(spinocerebellar
ataxia), MSA (Multiple system atrophy), SDS (Shy¨Drager syndrome),
olivopontocerebellar
atrophy, TIM (traumatic brain injury), CTE (chronic traumatic encephalopathy),
stroke, WKS
(Wemicke-Korsakoff syndrome; alcoholic dementia & thiamine deficiency), normal
pressure
hydrocephalus, hypersomnia/narcolepsy, ASD (autistic spectrum disorders), FXS
(fragile X
syndrome), TSC (tuberous sclerosis complex), prion-related diseases (CJD
etc.), depressive
disorders, DLB (dementia with Lewy bodies), PD (Parkinson's disease), PDD (PD
dementia),
and ADHD (attention deficit hyperactivity disorder).
[0025] In some embodiments the patient is a mammal. In
some embodiments the patient is
a human. In some embodiments the patient is a child human. In some embodiments
the patient
is an adult human. Child, as used herein, means a human from about 5 to 20
years of age.
Adult, as used herein, means a human from about 21 years of age and older.
9
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS
[0026] Some aspects and embodiments of the instant
disclosure are based, at least in part,
on the finding that partial agonism of an atA-AR receptor with a relatively
low dose of an atA-
AR partial agonist can increase cardiac output, resulting from improved venous
return and
myocardial contractility, without a concomitant substantial increase in
arteriolar vascular
resistance, thus resulting in an increase in blood flow to various parts of
the body, including
the brain. Therefore, compositions and methods are provided herein that
include identifying a
patient having a n0H, or a disease or disorder associated low cerebral blood
flow (CBF) and/or
fluctuations in CBF and administering to the patient an WA-AR partial agonist.
100271 In this regard, while not wishing to be bound to
any one particular theory, WA-AR
receptors are preferentially found on the venous vascular branches and on the
ventricular
cardiomyocytes. Activation of WA-AR receptors activates smooth muscles in the
venous
vascular branches, to lower venous capacitance and encourage blood return to
feed the heart,
and also activates the cardiomyocytes increasing pump action ¨ a cardiotonic
with a
physiological inotropic effect. With increased venous return, preload is
increased, thus raising
the filling volume of heart; with the inotropic effect, the ejection function
is enhanced, both
combining to deliver more output to the arteries¨and resulting in a reduction
of nOH
symptoms. However, unlike the indirect sympathomimetic droxidopa / Northera or
the non-
selective at-AR agonist midodrine, an atA-AR partial agonist, in certain
embodiments will
preferentially spare the arteriolar smooth muscles (largely finictioning via
am-AR and ato-AR
function), and so peripheral vascular resistance is not significantly raised
(reduced afterload'
elevation). As such, BP rise will be less strong (especially in the supine
position) and the
increased cardiac output will readily perfuse the organs and the brain.
[0028] Accordingly, the present disclosure includes
methods and compositions for treating
diseases, disorders, or conditions that are associated with, or caused by
impairment (or relative
decrease) in one or both of (a) cardiac output and (b) venous return.
[0029] In certain aspects and embodiments of the present
disclosure compositions and
methods result in an improved cognition, raised cerebral metabolic activity
and/or improved
inflammatory control in a patient. In some embodiments the methods described
herein result
in an improvement in cognition, for example as demonstrated by an improvement
in a cognition
test or model; a memory test; a diagnostic indicator of mental status, brain
function, mental
condition; a contextual learning test; or the like in the patient. Such
cognitive tests, diagnostics
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
and models are well known in the art In various aspects and embodiments, any
of many
accepted contextual learning tests for animals or humans can be used to assess
baseline
cognitive function and/or to measure or quantify improved cognitive function.
In some
embodiments, the compositions and methods described herein may result in an
improvement
one or more tests, diagnostics and models as follows. Likewise, for the raised
cerebral
metabolic activity and improved inflammatory control ¨ these in certain
embodiments may be
imaged via special methodologies including MRI (using arterial spin labelling
[ASL] and blood
oxygenation level dependent [BOLD], as well as positron emission tomography
approaches
such as FDG-PET, and via sampling of cerebrospinal fluid (CSF) allowing
measures of
inflammatory cytokines and markers of glial cell activation.
100301 Orthostatic hypotension (OH), also known as
postural hypotension, is a form of low
blood pressure which occurs when a person stands up In medical terms, OH is
defined as a
fall in systolic blood pressure of at least 20 or 30 mm Hg, or diastolic blood
pressure of at least
mm Hg within three minutes of a postural change from supine to upright
position
(Neurology 1996; 46:1470). OH can produce a wide variety of symptoms including
dizziness,
lightheadedness and syncope (fainting), as well as discomfort in the upper
chest and shoulder
region ('coat-hanger' pain). Due to these symptoms, OH often curtails or even
prevents daily
activities that require standing or walking. Additionally, OH is associated
with increased
morbidity and mortality. See, for example, Jones et al, Eacpert Review of
Cardiovascular
Therapy, 2015; 13:11, 1263-1276; Kuritzky et al , Postgrad. Med. 2015;
127(7):702-715; and
Low et al, J Girt. Neural., 2015; 11(3):220-226.
100311 The underlying causes of OH can be broadly divided
into neurogenic and non-
neurogenic categories. Neurogenic orthostatic hypotension (n0H) is a form of
OH involving
the nervous system, e.g., OH caused by a peripheral or central neurologic
disorder, such as
primary autonomic failure (including pure autonomic failure, multiple system
atrophy, and
Parkinson's disease), and autonomic neuropathy (dysautonomia) (including
diabetic and
nondiabetic autonomic neuropathy) (Arbique et al., JAMDA 15 (2014) 234-239).
Such
disorders can cause a deficiency or dysregulation of norepinephrine which is
the primary
neurotransmitter that regulates blood pressure in response to postural changes
(Loavenbruck et
al, Curr. Med. Res. Opin., 2015; 31:2095-2104). As a result, the autonomic
nervous system
fails to properly regulate blood pressure during a postural change and the
patient experiences
a significant fall in blood pressure resulting in, e.g., dizziness,
lightheadedness, or syncope.
11
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
[0032] Accordingly, the management of the nOH condition
requires, most fundamentally,
increasing cerebral blood flow (CBF) in the context of an otherwise
pathological fall in blood
pressure, on supine to standing posture changes in patients. In various
aspects and
embodiments of the compositions and methods provided herein, an atA-AR partial
agonist is
administered to a patient having nOH, and the actions of the partial agonist
make less frequent
and less severe associated signs and symptoms of nOH, including light-
headedness / dizziness,
pre-syncopal symptoms, syncope/blackout, and 'coat-hanger pain'. By
maintaining better
CBF, patients in some embodiments will also maintain improved cognitive
function, especially
those prone to 'fluctuations' which are commonly seen in the parkinsonism (or
'synucleinopathy') family of conditions often typically associated with nOH.
Symptoms/tests/screening for nOH and descriptions of some treatments can be
found in
Eschlbock et al, J Neural Tansm,(2017) 124:1567-1605 and Gibbons et al, J
Neurol, (2017)
264:1567-1582.
[0033] One objective of certain more traditional nOH
treatments is to increase levels of
norepinephrine in patients. One way to increase norepinephrine levels is to
administer an agent
that generates norepinephrine. For example, droxidopa (L-threo-3-4-
dihydroxyphenylserine)
is an amino acid that is converted by decarboxylation into norepinephrine in
both the central
and the peripheral nervous systems thereby increasing levels of norepinephrine
(Kaufinann et
al., Circulation, 2003; 108:724-728; Kaufmann, Clin. Autotz. Res. (2008)
18[Suppl 1]:19-24);
and Isaacson et al., Vascular Health and Risk Management, 2014, 10:169-176).
Droxidopa is
approved in the U.S. for the treatment of orthostatic dizziness, light-
headedness, or the "feeling
that you are about to black out" in adult patients with symptomatic nOH caused
by primary
autonomic failure (Parkinson's disease, multiple system atrophy, and pure
autonomic failure),
dopamine beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.
The main side
effect of droxidopa is supine hypertension and there is a black box warning in
the prescribing
information for this medication due to this serious side effect
[0034] Alternatively, norepinephrine levels can be
increased in patients by inhibiting the
norepinephrine transporter which is responsible for norepinephrine reuptake.
For example,
atomoxetine is a selective norepinephrine reuptake inhibitor approved in the
U.S. for treatment
of attention-deficit hyperactivity disorder (AMID). Atomoxetine has been shown
to increase
blood pressure in patients with central autonomic failure (Ramirez et al.,
Hypertension, 2014;
64:1235-40; and Shibao et al., Hypertension, 2007; 50:47-53). Atomoxetine,
however, is
12
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
metabolized primarily through the CYP2D6 enzymatic pathway and therefore, its
phannacokinetic properties are variable depending on whether the patient has
reduced
CYP2D6 activity (poor metabolize or normal CYP2D6 activity (extensive
metabolize (Ring
et at., Drug Metabolism and Distribution, 2002, 30:319-323). The prescribing
information for
atomoxetine also includes a number of warnings about possible drug-drug
interactions.
Additionally, when used to treat AMID, atomoxetine is associated with a number
of
gastrointestinal adverse effects including dry mouth and nausea. Atomoxetine
has not been
approved for the treatment of nOH.
100351 Other agents that historically have been used to
treat nOH include the al -
adrenoceptor full agonist, midodrine (and its active non-selective agonist
metabolite,
desglymidodrine); the synthetic mineralocorticoid, fludrocortisone; and the
cholinesterase
inhibitor, pyridostigmine. The side effects of these agents can include, for
midodrine, supine
hypertension, paraesthesias (including scalp-tingling), piloerection (goose
bumps), and urinary
urgency or retention; for fludrocortisone, hypokalemia, headaches, peripheral
edema, heart
failure and supine hypertension; and for pyridostigmine, abdominal discomfort
and urinary
urgency.
100361 In some embodiments, nOH can be diagnosed, for
example, by the patient reporting
signs and symptoms of nOH, including sway, light-headedness / dizziness, pre-
syncopal
symptoms, syncope/blackout, and 'coat-hanger pain'. Neurally-mediated
hypotension in some
embodiments can be diagnosed by using the so-called "tilt table test", which
reveals a drop in
blood pressure on moving a subject to near-upright position, and may reveal a
drop in heart
rate. In some cases, neurally- mediated hypotension (NMI-I) is diagnosed by a
drop in blood
pressure alone. In other cases, such diagnosis is only made when a drop in
blood pressure also
accompanies a drop in heart rate. The tilt table test measures heart rate and
blood pressure
while lying down (during resting state), then standing at a 70 degree angle
for 45 minutes. The
patient is lowered while medication, such as isoproterenol, is administered
through an IV to
increase the heart rate to about 10% above the resting heart rate and then the
patient is returned
to the 70 degree angle for 15 minutes. The medication is increased to further
increase the heart
rate, and the patient is returned to the upright position for 10 minutes.
Preferably, the test
environment is quiet and non-stimulating to eliminate distractions. The
patient may be required
to fast after midnight prior to the test (to reduce incidence of nausea and
vomiting). The patient
is strapped on the table to avoid injury in case of fainting and also to
decrease the human nature
13
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
of compensating for the blood pooling in the legs by "fidgetingTM. Patient
vital signs are
monitored throughout the tilt table test, and the test is determined to have a
positive result for
NNIH if there is a "significant" drop in blood pressure and a drop in heart
rate. As noted above,
some physicians consider a positive diagnosis with a drop in blood pressure
alone.
[0037] In one embodiment, an arA-AR partial agonist is
used to treat symptomatic nOH
caused by primary autonomic failure (including pure autonomic failure,
multiple system
atrophy and Parkinson's disease), or autonomic neuropathy (including diabetic
and nondiabetic
autonomic neuropathy). In one embodiment, an WA-AR partial agonist is used to
treat
symptomatic nOH caused by primary autonomic failure. In this embodiment, the
patient may
be diagnosed with pure autonomic failure, multiple system atrophy and/or
Parkinson's disease
In one embodiment, the patient has pure autonomic failure. In another
embodiment, the patient
has multiple system atrophy. And in another embodiment, the patient has
Parkinson's disease
Primary autonomic failure (also called primary dysautonomia) is a category of
dysautonomia,
i.e., a condition in which the autonomic nervous system does not function
properly. In primary
autonomic failure, the autonomic dysfunction occurs as a primary condition as
opposed to a
secondary condition resulting from another disease, such as diabetes. For
example, autonomic
failure is typically categorized as "primary" when it results from a chronic
condition
characterized by degeneration of the autonomic nervous system or where
autonomic failure is
the predominant symptom and its cause is unknown. Conditions categorized as
primary
autonomic failure include pure autonomic failure, multiple system atrophy, and
Parkinson's
disease.
[0038] Pure autonomic failure (PAF), also known as
Bradbury-Eggleston syndrome or
idiopathic orthostatic hypotension, is a degenerative disease of the autonomic
nervous system.
A primary symptom of PAF is orthostatic hypotension. Other symptoms may
include
decreased sweating, heat intolerance, urinary retention, bladder spasms
(possibly causing
incontinence), erectile dysfunction, fecal incontinence or constipation, and
pupillary
abnormalities. The cause of PAF is not completely understood, but the loss of
cells in the
intermediolateral column of the spinal cord has been documented in patients
with PAR.
Additionally, PAF may be related to abnormal accumulation of alpha-synuclein.
[0039] Parkinson's disease (PD) is a chronic and
progressive movement disorder. The
cause is unknown, but PD involves the malfunction and death of neurons in an
area of the
midbrain called the substantia nigra. These neurons produce dopamine which
plays a key role
14
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
in movement and coordination. As PD progresses, the amount of dopamine
produced in the
brain decreases resulting in motor control and coordination problems. Symptoms
include
tremor, rigidity, slowness of movement, and postural instability. However,
some PD patients
also experience non-motor symptoms including orthostatic hypotension due to
alterations in
the autonomic nervous system, i.e., PD plus symptoms of nOH. Additionally,
some patients
with PD symptoms have a condition known as Parkinson-plus syndromes (or
disorders of
multiple system degeneration). Parkinson-plus syndromes is a group of
neurodegenerative
diseases that produce the classical symptoms of PD (tremor, rigidity,
alcinesia/bradykinesia,
and postural instability) with additional features that distinguish them from
simple idiopathic
PD. Clinical features distinguishing Parkinson-plus syndromes from idiopathic
PD include
symmetrical onset, a lack of or irregular resting tremor, and a reduced
response to dopaminergic
drugs (including levodopa). Additional features include bradykinesia, early-
onset postural
instability, increased rigidity in axial muscles, dysautonomia, alien limb
syndrome,
supranuclear gaze palsy, apraxia, involvement of the cerebellum including the
pyramidal cells,
and in some instances significant cognitive impairment.
100401 Multiple system atrophy (MSA), also known as Shy-
Drager syndrome, is a
progressive neurodegenerative disorder characterized by a combination of
symptoms that
affect both the autonomic nervous system and movement. The initial symptoms of
MSA are
often difficult to distinguish from the initial symptoms of Parkinson's
disease and include
slowness of movement, tremor, or rigidity (stiffness); clumsiness or
incoordination; impaired
speech, a croaky, quivering voice; fainting or lightheadedness due to
orthostatic hypotension;
bladder control problems, such as a sudden urge to urinate or difficulty
emptying the bladder.
MSA is divided into two different types depending on the most prominent
symptoms at the
time an individual is evaluated: the parkinsonian type (MSA-P), with primary
characteristics
similar to Parkinson's disease (such as moving slowly, stiffness, and tremor)
along with
problems of balance, coordination, and autonomic nervous system dysfunction;
and the
cerebellar type (MSA-C), with primary symptoms featuring ataxia (problems with
balance and
coordination), difficulty swallowing, speech abnormalities or a quavering
voice, and abnormal
eye movements. The cause of MSA is unknown. A distinguishing feature of MSA is
the
accumulation of the protein alpha-synuclein in glia, the cells that support
nerve cells in the
brain. These deposits of alpha-synuclein particularly occur in
oligodendroglia, a type of cell
that makes myelin (a coating on nerve cells that lets them conduct electrical
signals rapidly).
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
A recent study indicates that a prion form of the alpha-synuclein protein may
be the cause of
the disease (Prusiner et al, PNAS, (2015) 112: E5308-17).
[0041] In one embodiment, an aiA-AR partial agonist is
used is used to treat symptomatic
nOH caused by autonomic neuropathy. Autonomic neuropathy, or dysautonomia,
refers to
various conditions in which the autonomic nervous system (ANS) does not work
properly.
Autonomic neuropathy is a type of neuropathy affecting the nerves that carry
information from
the brain and spinal cord to the heart, bladder, intestines, sweat glands,
pupils, and blood
vessels. The primary symptoms of autonomic neuropathy, which can vary between
individuals,
include: orthostatic hypotension; dry mouth; rapid heart rate; tunnel vision;
difficulty
swallowing; bowel incontinence; blurry vision; urinary incontinence;
constipation; anhydrosis;
and sexual disfunction. Autonomic neuropathy may be due to inherited or
degenerative
neurologic diseases (primary dysautonomia) or it may occur due to injury of
the autonomic
nervous system from an acquired disorder (secondary dysautonomia).
[0042] Riley and Espay, Journal of Clinical Movement
Disorders, (2018) 5:1 described a
patient having Parkinson's disease dementia (PDD) that experienced cognitive
fluctuations that
correlated with the patient's blood pressure. Accordingly, in some aspects and
embodiments,
a method is provided that includes identifying a patient diagnosed with, or in
need of treatment
for, a disease or condition associated with low cerebral blood flow (CBF)
and/or fluctuations
in CBF and administering to the patient an aiA-AR partial agonist; wherein the
patient treated
by the methods disclosed herein has experienced cognitive fluctuations; for
example cognitive
fluctuations associated with dementia with Lewy bodies (DLB) or with
Parkinson's disease
dementia (PDD).
[0043] There are many contextual learning tests used that
are acknowledged and/or
accepted in the art that in various embodiments may be used in conjunction
with the
compositions and methods disclosed herein to assess baseline cognitive
function and/or to
measure or quantify improved cognitive function in human subjects. For
example, the
contextual learning test used may be based upon single task learning, multiple
task learning or
spatial contextual memory. Contextual learning test evaluations based upon
spatial contextual
memory may be advantageous in assessing, for example, how well an individual
is able to
navigate a shopping mall, his or her neighborhood or a city transit or subway
system as well as
assessing any improvements in the ability to execute these tasks resulting
from the treatment
methods described herein.
16
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
100441
An example of a simple spatial
contextual learning test is contextual cuing, where
humans learn to use repeated spatial configurations to facilitate a target
search. A higher order
spatial contextual learning test is serial learning, where humans learn to use
subtle sequence
regularities to respond more quickly and accurately to a series of events.
See, for example, I
H. Howard Jr., et al., Neuropsychology, Vol. 18(1), January 2004, 124-134.
100451
In some embodiments, cognition
may be evaluated using the Mini-Mental State
Examination (MMSE) and/or the Montreal Cognitive Assessment (MOCA).
100461 Arizona Cognitive Test Battery (ACTB). A testing protocol that may be
used in
various embodiments is the Arizona Cognitive Test Battery (ACTB). See Edgin,
J., et al. J.
Neurodevelop. Disord. (2010) 2: 149-164. The ACTB has been developed
specifically to
assess the cognitive phenotype in DS, and includes various tests with various
task demands and
links with brain function. In more detail, tests are included for: 1)
benchmarks, such as KBIT
II verbal subscale and KBIT II non-verbal subscale IQ tests, 2) hippocampal
function, 3)
prefrontal function, 4) cerebellar function, 5) Finger sequencing tasks, 6)
NEPSY visuomotor
precision and 7) simple reaction time.
100471
A correlation of domain/test,
test description and primary ability assessed in
accordance with the ACTB is provided below:
Domain/Test Description
Primary Ability Assessed
1) Benchmark Points to pictures based on word or
KBIT-II verbal subscale phrase
Verbal comprehension
Semantic or visuo-spatial
Problem solving
KBIT-II nonverbal subscale
pattern completion
2) CANTAB spatial span
Touching boxes in order of Immediate memory for
changing color on screen
spatial-temporal sequence
Press button below a cat, shifts to
3) Prefrontal Modified dots Inhibitory control
new rule, press across screen for a
task working memory
frog, etc.
Forced-choice discrimination task
4) CANTAB IED Set-shifting
with change in relevant dimension
5) Hippocampal CANTAB Spatial associative
Recall for hidden abstract patterns
paired associates
memory
6) Virtual computer- Navigation of a virtual arena (via
Spatial memory
generated arena joystick) to find a hidden
target
17
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
Domain/Test Description
Primary Ability Assessed
)
Sequences generated by tapping a
7 Cerebellar
number of fingers (1, 2, 3, 4) to a Motor sequencing
Finger-sequencing task
lever in succession
8) NEPSY visuo-motor Visuo-motor tracking,
Follows two tracks with a pen
precision
hand-eye coord.
. Participants press button
in
9) CANTAB simple reaction Motor response time and
response to a box presented on a
time
attention
screen
100481 With respect to the agents described herein, the terms "modulate" and
"modulation"
refers to the upregulation (i.e., activation or stimulation) or downregulation
(i.e., inhibition or
suppression) of a response. A "modulator" is an agent, compound, or molecule
that modulates,
and may be, for example, an agonist, antagonist, activator, stimulator,
suppressor, or inhibitor.
The terms "inhibit", "reduce", remove as used herein refer to any inhibition,
reduction,
decrease, suppression, downregulation, or prevention in expression, activity
or symptom and
include partial or complete inhibition of activity or symptom. Partial
inhibition can imply a
level of expression, activity or symptom that is, for example, less than 95%,
less than 90%, less
than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less
than 60%, less than
55%, less than 50%, less than 45%, less than 40%, less than 35%, less than
30%, less than 25%,
less than 20%, less than 15%, less than 10%, or less than 5% of the
uninhibited expression,
activity or symptom. The terms "eliminate" or "eradicate" indicate a complete
reduction of
activity or symptom.
100491 As used herein, the term "a disorder" or "a
disease" refers to any derangement or
abnormality of function; a morbid physical or mental state. See Dorland's
Illustrated Medical
Dictionary, (W.B. Saunders Co. 27th ed. 1988).
100501 As used herein, the term "treating" or "treatment"
of any disease or disorder refers
in one embodiment, to ameliorating the disease or disorder (i.e., slowing or
arresting or
reducing the development of the disease or at least one of the clinical
symptoms thereof) In
another embodiment "treating" or "treatment" refers to alleviating or
ameliorating at least one
physical parameter including those which may not be discernible by the
patient. In yet another
embodiment, "treating" or "treatment" refers to modulating the disease or
disorder, either
physically, (e.g., stabilization of a discernible symptom), physiologically,
(e.g., stabilization of
18
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
a physical parameter), or both. In yet another embodiment, "treating" or
"treatment" refers to
preventing or delaying the onset or development or progression of the disease
or disorder.
[0051]
In some embodiments,
contemplated methods may include for example,
administering prodrugs of the compounds described herein, or a pharmaceutical
composition
thereof The term "prodrug" refers to compounds that are transformed in vivo to
yield a
disclosed compound or a pharmaceutically acceptable salt, hydrate or solvate
of the compound.
The transformation may occur by various mechanisms (such as by esterase,
amidase,
phosphatase, oxidative and or reductive metabolism) in various locations (such
as in the
intestinal lumen or upon transit of the intestine, blood or liver). Prodrugs
are well known in the
art (for example, see Rautio, Kumpulainen, et al., Nature Reviews Drug
Discovery 2008, 7,
255). In some embodiments, the prodrug structures are constructed according to
the disclosure
in United States Patent Number 9,849,134, which is incorporated by reference
herein in the
entirety.
[0052]
For example, if a compound of
the disclosure or a pharmaceutically acceptable salt,
hydrate or solvate of the compound contains a carboxylic acid functional
group, a prodrug can
comprise an ester formed by the replacement of the hydrogen atom of the acid
group with a
group such as (Ci-s)alkyl, (C2-12)alkylcarbonyloxymethyl, 1-
(alkylcarbonyloxy)ethyl having
from 4 to 9 carbon atoms, 1-methyl-14alkylcarbonyloxy)-ethyl having from 5 to
10 carbon
atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-
(alkoxycarbonyl oxy)ethyl having from 4 to 7 carbon atoms, 1-methyl -1-
(alkoxycarbonyl oxy)ethyl having from 5 to 8 carbon atoms, N-
(alkoxycarbonyl)aminomethyl
having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from
4 to 10
carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-
-(Ci-
2)alkylamino-(C2-3)alkyl (such as 13-dimethylaminoethyl), carbamoy1-(C1-
2)alkyl, N,N-di(Ci.
2)alkylcarbamoyl-(C1-2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-
3)alkyl.
[0053]
Similarly, if a compound of
the disclosure contains an alcohol functional group,
a prodrug can be formed by the replacement of the hydrogen atom of the alcohol
group with a
group such as (C1-6)alkylcarbonyloxymethyl, 14(C14alkylcarbonyloxy)ethyl, 1-
methyl-1-
((C1-6)al kyl carbonyl oxy)ethyl (C1-
6)alkoxycarbonyloxy)methyl, N--(Ci-
6)alkoxycarbonylaminomethyl, succinoyl, (C1-6)alkylcarbonyl, a-amino(C1-
4)alkylcarbonyl,
arylalkylcarbonyl and a-aminoalkylcarbonyl, or a-aminoalkylcarbonyl a-
aminoalkylcarbonyl,
where each a-aminoalkylcarbonyl group is independently selected from the
naturally occurring
19
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
L-amino acids, P(0)(OH)2, --P(0)(0(C1-6)alky1)2 or glycosyl (the radical
resulting from the
removal of a hydroxyl group of the hemiacetal form of a carbohydrate).
100541 If a compound of the disclosure incorporates an
amine functional group,
a prodrug can be formed, for example, by creation of an amide or carbamate, an
N-
allcylcarbonyloxyalkyl derivative, an (oxodioxolenyOmethyl derivative, an N-
Mannich base,
imine or enamine. In addition, a secondary amine can be metabolically cleaved
to generate a
bioactive primary amine, or a tertiary amine can metabolically cleaved to
generate a bioactive
primary or secondary amine. For examples, see Simplicio, et at., Molecules
2008, 13, 519 and
references therein.
100551 "Therapeutically effective amount" as used herein
means the amount of a
compound or composition (such as described herein) that causes at least one
desirable change
in a cell, population of cells, tissue, individual, patient or the like. In
some embodiments a
therapeutically effective amount as used herein means the amount of a compound
or
composition (such as described herein) that prevents or provides a clinically
significant change
in a disease or condition (e.g., reduce by at least about 30 percent, at least
about 50 percent, or
at least about 90 percent) or in one or more features of a disease or
condition described herein.
Dosage, Administration and Pharmaceutical Formulation
100561 The term "pharmaceutically-accepted salts" means
acid addition salts that are
commonly used in human or veterinary medicine and are deemed safe for use.
Examples for
the present disclosure include, but are not limited to, salts obtained from
the following acids:
acetic, ascorbic, benzenesulfonic, benzoic, camphosulfonic, citric,
ethanesulfonic, edisylic,
fumaric, gentisic, gluconic, glucoronic, glutamic, hippuric, hydrobromic,
isethionic, lactic,
nitric, phosphoric, succinic, sulfuric and tartaric, for example. Any hydrated
forms of such
salts are also included in this definition. Thus, for example, both fumarate
and hemifumarate
salts are specifically contemplated as well as any hydrates thereof For
example, fumarate
dihydrate may be specifically mentioned.
100571 The pharmaceutical preparation in some embodiments
may be in unit dosage form.
In such form the preparation is subdivided into unit doses containing
appropriate quantities of
the active component. The unit dosage form can be a packaged preparation, the
package
containing discrete quantities of preparation, such as packeted tablets,
capsules, and powders
in vials or ampoules. Also, the unit dosage form can be a capsule, tablet,
cachet, or lozenge
itself, or it can be the appropriate number of any of these in packaged form.
The composition
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
can, if desired, also contain other compatible therapeutic agents. Preferred
pharmaceutical
preparations can deliver the compounds of the disclosure in a sustained
release formulation.
[0058]
For a binding agent,
composition, or compound according to the present disclosure,
the dosage form may optionally be a liquid dosage form. Solutions can be
prepared in water
suitably mixed with a surfactant such as hydroxypropylcellulose or an
emulsifier such as
polysorbate. Dispersions can also be prepared in glycerol, liquid polyethylene
glycols, DMSO
and mixtures thereof with or without alcohol, and in oils. Under ordinary
conditions of storage
and use, these preparations contain a preservative to prevent the growth of
microorganisms.
Conventional procedures and ingredients for the selection and preparation of
suitable
formulations are described, for example, in Remington's Pharmaceutical
Sciences (2003-20th
edition) and in The United States Pharmacopeia: The National Formulary (USP 24
NF19)
published in 1999. Formulations optionally contain excipients including, but
not limited to, a
buffering agents, an anti-oxidant, a stabilizer, a carrier, a diluent, and an
agent for pI4
adjustment The pharmaceutical forms suitable for injectable use include
sterile aqueous
solutions or dispersion and sterile powders for the extemporaneous preparation
of sterile
injectable solutions or dispersions. Acceptable carriers, excipients, or
stabilizers are nontoxic
to recipients at the dosages and concentrations employed, and include buffers
such as
phosphate, citrate, and other organic acids; antioxidants including ascorbic
acid and
methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride;
hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol,
butyl, or
benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol;
resorcinol;
cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about
10 residues)
polypeptides; proteins such as serum, albumin, gelatin, or immunoglobulins;
hydrophilic
polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine,
histidine, arginine or lysine; monosaccharides, disaccharides, and other
carbohydrates
including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars
such as
sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal
complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as
TWEEN,
PLURONICS or polyethylene glycol (PEG).
[0059]
In certain embodiments, an
agent in accordance with the methods provided herein
is administered subcutaneously (s.c.), intravenously (i.v.), intramuscularly
(i.m.), intranasally
or topically. Administration of an agent described herein can, independently,
be one to four
21
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
times daily or one to four times per month or one to six times per year or
once every two, three,
four or five years. Administration can be for the duration of one day or one
month, two months,
three months, six months, one year, two years, three years, and may even be
for the life of the
human patient. The dosage may be administered as a single dose or divided into
multiple doses.
In some embodiments, an agent is administered about 1 to about 3 times (e.g.
1, or 2 or 3 times).
EXAMPLES
100601 The present disclosure will be further described
in the following examples, which
do not limit the scope of the present disclosure.
EXAMPLE 1: TREATMENT OF A PATIENT HAVING NOW
100611 Patients between the age of 40 and 80 years old
that have been diagnosed with
symptomatic orthostatic hypotension due to pure autonomic failure, multiple
system atrophy
or Parkinson's disease (i.e., PD plus symptoms) present for treatment. At the
time of
presentation, autonomic function testing is conducted to confirm the diagnosis
of autonomic
dysfunction including sinus arrhythmia and the Valsalva maneuver. The
patients: (1)
demonstrate a 3O mm Hg drop in SBP within 5 minutes of standing; (2)
demonstrate
impaired autonomic reflexes as determined by absence of BP overshoot during
phase IV of the
Valsalva maneuver; (3) experience dizziness, light-headedness, or fainting
when standing; and
(4) have an absence of other identifiable causes of autonomic neuropathy.
100621 The patients are given 5 mg dabuzalgron oral
tablets and are instructed to take one
tablet shortly after waking up in the morning and a second tablet 4-6 hours
later each day.
100631 Some patients return for a follow-up visit after
one week of treatment. It is expected
that the symptoms of nOH improve as compared to the first visit before
dabulzagron treatment.
In the follow-up visit supine systolic blood pressure (SSBP) may be
determined. It is expected
that patients taking dabulzagron will not experience a substantial rise in
SSBP; and/or the rise
in SSBP is less that that observed in patients taking midodrine or droxidopa
for n014.
100641 The disclosures illustratively described herein
may suitably be practiced in the
absence of any element or elements, limitation or limitations, not
specifically disclosed herein.
Thus, for example, the terms "comprising," "including," "containing," etc.
shall be read
expansively and without limitation. Additionally, the terms and expressions
employed herein
have been used as terms of description and not of limitation, and there is no
intention in the use
of such terms and expressions of excluding any equivalents of the features
shown and described
22
CA 03153305 2022-3-31
WO 2021/081292
PCT/US2020/057001
or portions thereof, but it is recognized that various modifications are
possible within the scope
of the claims.
[0065] While the disclosure has been particularly shown
and described with reference to
specific embodiments (some of which are preferred embodiments), it should be
understood by
those having skill in the art that various changes in form and detail may be
made therein without
departing from the spirit and scope of the present disclosure as disclosed
herein.
[0066] Various embodiments of the present disclosure may
be characterized by the
potential claims listed in the paragraphs following this paragraph (and before
the actual claims
provided at the end of this application). These potential claims form a part
of the written
description of this application. Accordingly, subject matter of the following
potential claims
may be presented as actual claims in later proceedings involving this
application or any
application claiming priority based on this application. Inclusion of such
potential claims
should not be construed to mean that the actual claims do not cover the
subject matter of the
potential claims. Thus, a decision to not present these potential claims in
later proceedings
should not be construed as a donation of the subject matter to the public.
[0067] The embodiments of the disclosure described above
are intended to be merely
exemplary; numerous variations and modifications will be apparent to those
skilled in the art.
All such variations and modifications are intended to be within the scope of
the present
disclosure as defined in any appended claims.
[0068] All publications, patent applications, patents,
and other references mentioned herein
are expressly incorporated by reference in their entirety, to the same extent
as if each
were incorporated by reference individually. In case of conflict, the present
specification,
including definitions, will control.
[0069] Although the invention has been described with
reference to the above examples, it
will be understood that modifications and variations are encompassed within
the spirit and
scope of the invention_ Accordingly, the invention is limited only by the
following claims.
23
CA 03153305 2022-3-31
